Kitadai Rui, Okuma Yusuke, Kashima Jumpei
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Case Rep Oncol. 2019 Feb 20;12(1):171-177. doi: 10.1159/000497481. eCollection 2019 Jan-Apr.
Metastasis to oral soft tissues is rare and account for only 0.1% of all oral malignancies. Oral cavity metastasis tends to be male-predominant, and lung cancer is the leading cause. Targeted therapies for advanced ALK rearranged non-small cell lung cancer (NSCLC) have shown a promising higher response than cytotoxic chemotherapy. Gingival metastasis usually shows poor prognosis. However using ALK inhibitor to ALK-positive advanced NSCLC may show longer survival.
A 64-year-old male who was diagnosed non-small cell carcinoma (NSCC) favoring adenocarcinoma presented with gingival metastasis. After first-line chemotherapy, ALK rearrangement was revealed in both primary lesion and gingival metastasis, and therefore the patient was treated with alectinib. Tumor response of the primary site and gingival lesion were obtained, however he presented with intestinal metastasis that lead to bowel obstruction and passed away.
Our case showed good response to primary tumor and gingival metastasis but not to intestinal obstruction. ALK inhibitor often shows high response rate and long survival for ALK rearrangement NSCLC, however ALK rearranged positive NSCLC with gingival metastasis may have poor prognosis.
口腔软组织转移罕见,仅占所有口腔恶性肿瘤的0.1%。口腔转移以男性为主,肺癌是主要病因。针对晚期ALK重排非小细胞肺癌(NSCLC)的靶向治疗显示出比细胞毒性化疗更有前景的更高缓解率。牙龈转移通常预后较差。然而,使用ALK抑制剂治疗ALK阳性晚期NSCLC可能会延长生存期。
一名64岁男性,诊断为倾向腺癌的非小细胞癌(NSCC),出现牙龈转移。一线化疗后,在原发灶和牙龈转移灶均发现ALK重排,因此患者接受阿来替尼治疗。原发部位和牙龈病变获得了肿瘤缓解,但他出现了肠转移,导致肠梗阻并死亡。
我们的病例显示对原发肿瘤和牙龈转移有良好反应,但对肠梗阻无效。ALK抑制剂对ALK重排的NSCLC通常显示出高缓解率和长生存期,然而,伴有牙龈转移的ALK重排阳性NSCLC可能预后较差。